



57332_Auto_Edited.docx

Quotes Excluded
Bibliography Excluded

11%
SIMILAR

11

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 57332

Manuscript Type: CASE REPORT

Chemotherapy rechallenge in metastatic colon cancer: A case report

Tejaswini Parlapalle Reddy, Usman Khan, Ethan Alexander Burns, Maen Abdelrahim

Abstract

BACKGROUND

Colorectal cancer (CRC) is the third leading cause of cancer-related death in males and females in the United States. Approximately, 20%-22% of patients have metastatic disease at the time of presentation, and 50%-60% will develop metastasis over the course of their disease. Despite advances in systemic therapies, there remains a paucity of effective third- and later-line therapies for patients with ongoing disease progression. However, rechallenging chemo-resistant CRC tumors with previously administered therapies is an emerging concept that may be a life-prolonging option for heavily treated metastatic colorectal cancer (mCRC).

CASE SUMMARY

A 41-year-old man with no previous medical history initially presented with worsening diffuse abdominal tenderness. Computed tomography was significant for a splenic

Match Overview

1	Internet 122 words crawled on 24-Nov-2017 www.dovepress.com	4%
2	Crossref 28 words Mitsukuni Suenaga , Takeru Wakatsuki , Tetsuo Mashima , Mariko Ogura et al. "A phase I study to determine the max	1%
3	Internet 23 words crawled on 01-Sep-2020 jncn.org	1%
4	Internet 22 words crawled on 29-Sep-2020 www.wjgnet.com	1%
5	Internet 19 words crawled on 18-May-2020 www.science.gov	1%
6	Crossref 17 words Sarah Besora , Cristina Santos , Cristina Izquierdo , Maria Mercedes Martinez-Villacampa , Jordi Bruna , Roser Velas	1%
7	Internet 16 words crawled on 18-Sep-2020 journals.lww.com	1%
8	Crossref 15 words Karan Tan , Sei Mun Leong , Zizheng Keo , Patrick Vincent	1%



Oxaliplatin based systemic chemotherapy Rechallenge in a Chemotherap



Sign in



ALL

IMAGES

VIDEOS

18,700 Results

Any time ▾

Hypersensitivity to oxaliplatin: clinical features and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896838>

Jan 13, 2014 · **Oxaliplatin**, a third-generation platinum agent, has been approved for the treatment of **metastatic** colorectal **cancer** and for adjuvant treatment in stage-III **colon cancer** . It is also used worldwide in other malignancies, such as ovarian **cancer** [5].

Cited by: 66

Author: Marie Parel, Florence Ranchon, Audrey ...

Publish Year: 2014

Oxaliplatin-induced severe anaphylactic reactions in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471112>

Oct 14, 2012 · AIM: To investigate **oxaliplatin**-induced severe anaphylactic reactions (SAR) in **metastatic** colorectal **cancer** in a retrospective **case** series analysis and to conduct a **systemic literature review**. METHODS: During a 6-year period from 2006 to 2011 at Kaohsiung Veterans General Hospital, a total of 412 **patients** exposed to **oxaliplatin**-related ...

Cited by: 11

Author: Jui-Ho Wang, Tai-Ming King, Min-Chi Cha...

Search Tools

Turn off Hover Translation (关闭取词)



ALL

IMAGES

VIDEOS

422,000 Results

Any time ▼

Pseudoprogression during treatment with pembrolizumab ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637362>

Pseudoprogression during treatment with pembrolizumab followed by **rechallenge** with **chemotherapy** in **metastatic colorectal cancer**: A case report. Clin Case Rep. 2019; 7:1445–1449. 10.1002/ccr3.2262 [Google Scholar] Funding information. The Cancer Foundation and the Regional Strategic Council for Research in the Region of Southern Denmark.

Author: Natacha Dencker Trabjerg, Christina Ra...

Publish Year: 2019

Is there a role for rechallenge and reintroduction of anti ...

<https://ecancer.org/en/journal/article/1069-is-there-a-role-for-rechallenge-and...> ▼

Introduction. **Colorectal cancer** is a leading cause of **cancer**-related death []. Approximately 25% of all **colon cancer** patients will have advanced disease at diagnosis and almost 50% will eventually recur during the course of their disease []. Progress in systemic treatment seen in recent years has resulted in prolonged survival for patients with **metastatic** disease [].

Author: Amanda Karani, Tiago Cordeiro Felismi...

Publish Year: 2020

[PDF] Rechallenge and maintenance therapy using ... - BMC Cancer

<https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-017-3133-8>

CASE REPORT Open Access **Rechallenge** and **maintenance therapy** using cetuximab and **chemotherapy** administered to a patient with **metastatic colorectal cancer** Jian Ma, Quan-liang Yang and Yang Ling* Abstract Background: Cetuximab combined with **chemotherapy** is one of the first-line treatments of **metastatic colorectal cancer**.

Cited by: 3

Author: Jian Ma, Quan-liang Yang, Yang Ling

Publish Year: 2017

Is there a role for rechallenge and reintroduction of anti ...

<https://ecancer.org/en/journal/article/1069-is-there-a-role-for-rechallenge-and...> ▼

Jul 10, 2020 · The aim of our study was to evaluate efficacy of anti-EGFR **rechallenge** (ReCH) and reintroduction (ReIn) in **metastatic colorectal cancer** (mCRC). Materials and methods: This is a retrospective analysis of patients with mCRC that previously received anti-EGFR CT and interrupted therapy due to PD in the ReCH group and other reasons in the ReIn group.

Author: Amanda Karani, Tiago Cordeiro Felismi...

Publish Year: 2020

Unresectable metastatic colorectal cancer patient cured ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087863>

Cetuximab-based **chemotherapy** is a standard of care for patients with **RAS wild-type metastatic**

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

420,000 Results

Any time ▼

[Pseudoprogression during treatment with pembrolizumab ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637362>

Pseudoprogression during treatment with pembrolizumab followed by **rechallenge** with **chemotherapy** in **metastatic colorectal cancer**: A case report. Clin Case Rep. 2019; 7:1445–1449. 10.1002/ccr3.2262 [Google Scholar] Funding information. The **Cancer** Foundation and the Regional Strategic Council for Research in the Region of Southern Denmark.

Author: Natacha Dencker Trabjerg, Christina ... **Publish Year:** 2019

[\[PDF\] Rechallenge and maintenance therapy using ... - BMC Cancer](#)

<https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-017-3133-8>

CASE REPORT Open Access **Rechallenge** and **maintenance therapy** using cetuximab and **chemotherapy** administered to a patient with **metastatic colorectal cancer** Jian Ma, Quan-liang Yang and Yang Ling* Abstract Background: Cetuximab combined with **chemotherapy** is one of the first-line treatments of **metastatic colorectal cancer**.

Cited by: 3 **Author:** Jian Ma, Quan-liang Yang, Yang Ling
Publish Year: 2017

[Is there a role for rechallenge and reintroduction of anti ...](#)

<https://ecancer.org/en/journal/article/1069-is-there-a-role-for-rechallenge-and...> ▼

Jul 10, 2020 · The aim of our study was to evaluate efficacy of anti-EGFR **rechallenge** (ReCH) and reintroduction (ReIn) in **metastatic colorectal cancer** (mCRC). Materials and methods: This is a retrospective analysis of patients with mCRC that previously received anti-EGFR CT and interrupted therapy due to PD in the ReCH group and other reasons in the ReIn group.

Author: Amanda Karani, Tiago Cordeiro Felis... **Publish Year:** 2020

[Rechallenge and maintenance therapy using ... - BMC Cancer](#)

<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3133-8> ▼

Feb 14, 2017 · Background Cetuximab combined with **chemotherapy** is one of the first-line treatments of **metastatic colorectal cancer**. Although **disease progression** inevitably occurs, **rechallenge** and **maintenance therapies** using cetuximab-based **regimens** may be beneficial, particularly for patients with wild-type (WT) KRAS.